- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01218906
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a Phase 3 efficacy trial of a vaccine to prevent dengue infection.
The primary objectives are:
- To identify acute febrile episodes among the cohort in order to detect the presence of dengue infection.
- To develop operational infrastructure for potential Phase III dengue efficacy trial sites.
- To describe the dengue seroprevalence among the cohort at baseline and at the end of the study.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
All participants will make two visits to a study site, an enrollment visit and a termination visit. Additional visits will be made if febrile episodes occur: an acute visit and a convalescent visit. Participants or their parents/guardians will be contacted weekly to monitor the occurrence of febrile episodes and ensure appropriate assessment and care.
No vaccine will be provided or administered in this study.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Cebu City, Filippinene, 6000
-
Muntinlupa City, Filippinene
-
San Pablo, Filippinene
-
-
-
-
-
Bali, Indonesia
-
Bandung, Indonesia, 40161
-
Jakarta, Indonesia, 10430
-
-
-
-
-
Kuala Lumpur, Malaysia
-
Penang, Malaysia
-
Putrajaya, Malaysia
-
-
-
-
-
Bangkok, Thailand, 10400
-
-
-
-
-
My Tho City, Vietnam
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria :
- Aged 2 to 14 years on the day of inclusion and resident of the site zone
- Subject in good health, based on medical history and physical examination
- Assent form has been signed and dated by the subject (if required by local regulations), and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (and by the subject and/or an independent witness if required by local regulations)
- Subject able to attend all scheduled visits and to comply with all study procedures
- For a female of childbearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to enrollment.
Exclusion Criteria :
- Known pregnancy at the Enrollment Visit
- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding enrollment
- Planned participation in another clinical trial during the present study period
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection
- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
- Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with study procedures
- Receipt of blood or blood-derived products in the past 3 months
- Receipt of any vaccine in the 4 weeks preceding the day of enrollment except for pandemic influenza vaccination, which may be received at least 2 weeks before enrollment
- Planned receipt of any vaccine in the 4 weeks following enrollment
- Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
Temporary Contraindications
A prospective subject should not be included in the study until the following condition and/or symptoms are resolved:
- Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of enrollment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Cohort Population (Case )
Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To provide information on the incidences of febrile episodes and confirmed and probable Dengue fever, and to determine other causes of febrile episodes in the cohort population
Tidsramme: Up to 12 months after enrollment
|
Up to 12 months after enrollment
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Medical Director, Sanofi Pasteur SA.
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CYD34
- U1111-1112-8378 (Annen identifikator: WHO)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .